The Prescription Price Game

A low copay can hide a high price. Here is how the system shifts cost and control onto patients.

When healthcare functions primarily as a profit center, a basic question gets harder to answer: who controls access to essential medicine, and who ultimately pays for it?

At the pharmacy counter, a patient may pay a twenty-dollar copay and leave believing the insurance system has done its job. In that immediate moment, it has. The medicine is in hand, and the upfront expense is manageable.

What remains hidden is the larger financial machinery behind the transaction. The pharmacy may receive hundreds or thousands of dollars. The insurer pays its share, an employer may finance part of the health plan, and public programs such as Medicare, Medicaid, and TRICARE bring taxpayers into the payment chain. Rebates, administrative fees, and later adjustments move money around after the prescription has left the shelf.

A low copay does not prove that the medicine was inexpensive. It may only mean that most of the cost was shifted somewhere else.

When the Cost Becomes Control

Healthcare has real costs. Treatments must be researched, developed, manufactured, transported, dispensed, and monitored. Doctors, nurses, pharmacists, and support staff deserve fair compensation. The problem begins when every link in that chain becomes an opportunity to maximize revenue without a corresponding improvement in care, affordability, or access.

One prescription can generate revenue for a manufacturer, wholesaler, insurer, pharmacy benefit manager, retail or specialty pharmacy, health system, government contractor, and the investors behind them. The patient experiences a treatment. The organizations involved see contracts, margins, rebates, fees, and future earnings.

Pharmacy benefit managers, or PBMs, are one part of this system, but they are not the only source of the problem. PBMs began as claims processors and network administrators. Those functions can be useful. Over time, the largest PBMs gained substantial influence over formularies, pharmacy networks, dispensing payments, and rules that require patients to try a lower-cost option before receiving the prescribed treatment.

The deeper issue is that financial incentives now run through every stage of care. When an insurer, PBM, and pharmacy share corporate ownership, the organization managing the prescription may also profit from where it is dispensed, how it is reimbursed, and which product receives preferred coverage. Different logos do not necessarily mean independent economic interests.

As drug spending rises, payers look for ways to contain it. That pressure can appear as prior authorization, step therapy, quantity limits, restrictive formularies, higher cost-sharing tiers, mandatory specialty pharmacies, or coverage exclusions. Some controls serve legitimate medical purposes, such as preventing unsafe prescribing or duplicate treatment. But when high underlying prices create the crisis, access controls can become a substitute for reforming the price itself.

A patient can therefore have valid insurance, a doctor's prescription, and a genuine medical need, yet still face delays, denials, or unaffordable out-of-pocket costs. The patient is insured on paper but not necessarily protected in practice.

The consequences extend beyond a single transaction. A low copay can mask an unsustainable system until the cost returns as higher premiums, larger deductibles, reduced employer benefits, public spending pressure, or harsher coverage rules. When opaque pricing is accepted because the immediate copay looks manageable, the system loses an incentive to become simpler, cheaper, and more accountable.

Try This

Patients cannot redesign the healthcare system from the pharmacy counter. They can, however, expose hidden costs and access barriers before a small obstacle becomes a treatment crisis.

Action	Why it matters
Compare the insured price with a legitimate cash price.	Insurance is not automatically the cheapest route.
Ask whether a cash purchase counts toward your deductible and annual out-of-pocket limit.	A lower price today may provide no credit toward future insurance costs.
Check for prior authorization, step therapy, quantity limits, or a required pharmacy.	Knowing the rules early can prevent a treatment delay later.
Discuss medically appropriate alternatives with the prescriber or pharmacist.	The goal is effective treatment at a sustainable cost, not simply the cheapest medicine.
Request the reason for a denial in writing and ask about an exception or appeal.	A coverage denial is not always the final decision.
Tell the plan administrator when an employer-sponsored plan repeatedly creates unreasonable costs or access barriers.	Employers need evidence of how benefit arrangements work in real life.

Understanding the Anatomy of a Price

A single medicine can carry several prices at once. The manufacturer publishes a list price. The pharmacy pays an acquisition cost. A cash-paying customer may see another price. An insurer processes an insured claim at a contracted amount. The patient may pay a copay, coinsurance, or deductible, while rebates and fees move through the system later. The final net cost can be very different from the number shown at the pharmacy counter.

Price category	What it represents
List price	The manufacturer's published starting price
Acquisition cost	What the pharmacy may pay to obtain the medicine
Cash price	What a patient may pay without using insurance
Insured reimbursement	What the plan pays the pharmacy
Patient cost-sharing	Copay, coinsurance, or deductible
Net cost	What remains after rebates and other adjustments

These figures are not interchangeable. Acquisition cost is not always the cash price, and reimbursement is not always the final net cost. Large gaps still matter because patient cost-sharing, employer spending, and public budgets can be influenced by prices that appear before later rebates and adjustments.

A Federal Trade Commission staff report illustrates the scale of the problem in specialty generic medicines handled by the largest PBMs and their affiliated pharmacies. For commercial claims in 2022, pharmacies acquired dimethyl fumarate, used to treat multiple sclerosis, for an average of about $177. The average markup was about $3,753, and affiliated pharmacies were paid about $3,930 for a 30-day supply. The report also found that tadalafil, used for pulmonary hypertension, had an average acquisition cost of about $27 while affiliated pharmacies were paid about $2,106 for a 30-day supply.

The FTC report also examined insulin. Staff alleged that the largest PBMs and affiliated purchasing organizations favored products with high list prices and large rebates over lower-list-price alternatives. The allegation is not that every rebate is improper or that PBMs alone created the drug-pricing crisis. The concern is that a system rewarding larger rebates can give manufacturers a reason to compete through higher starting prices instead of lower prices at the point of sale.

These examples do not prove that every transaction is abusive, and they do not make one organization responsible for the entire system. They do show why prescription economics must be visible enough for patients, employers, and public purchasers to tell whether the system is reducing the cost of care or merely moving money to a different part of the same system.

Bottom Line

The prescription-pricing dilemma is bigger than the actions of PBMs alone. It is the predictable result of a system in which healthcare is treated as a profit center and chronic illness creates captive demand.

The patient sees a treatment. The institutions involved see revenue. A manageable copay can conceal an unsustainable transaction, and when costs mount, the system often responds with tighter gatekeeping: which medicines are covered, which pharmacies may dispense them, and which patients must clear extra hurdles.

The essential questions are simple: What does the treatment really cost? Who profits from the exchange? Who carries the burden when the price becomes unsustainable? Until those incentives change, rising prices will continue to be managed through restricted access instead of honest price reform.

This wider relationship between money, institutions, and medical care is explored in The Business of Healing, available worldwide on Amazon.

Source note: The specialty-generic examples above are drawn from the Federal Trade Commission staff report Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers. The report describes staff findings and does not, by itself, establish that every transaction was unlawful.

Why Government Reform Moves Slowly

PBMs were not created by one law or one political decision. They grew from private claims-processing and benefit-management businesses, then became deeply embedded in employer insurance and Medicare drug coverage. Medicare Part D, for example, is administered through private plan sponsors, many of which use or own PBMs to manage formularies, pharmacy networks and drug-price negotiations. https://www.gao.gov/products/gao-19-498

By the time the problem became visible, the money and authority had been divided among manufacturers, insurers, PBMs, pharmacies, employers, government programs and state regulators. No single participant sees the complete transaction or has a simple incentive to change it. Patients see their copay. Employers see the cost of their health plan. Insurers see claims and premiums. Government sees public spending. Each group faces only part of the bill.

Lawmakers also face a fragmented legal framework. Federal rules govern employer health plans and Medicare, while states regulate many insurance and pharmacy practices. State attempts to regulate PBMs can face challenges under ERISA and Medicare pre-emption rules, creating uneven regulation across the country. https://www.congress.gov/crs-product/LSB11080

The industry has also become complex enough to adapt when one source of revenue is restricted. A rule may limit spread pricing, rebate retention or one form of pharmacy steering, while compensation shifts into another fee, affiliate relationship or contract. Transparency can expose part of the problem without changing the underlying conflict created by common ownership.

Congress can hold hearings, regulators can investigate and states can pass reforms. Those actions matter, but they do not automatically separate the insurer, the PBM and the pharmacy, or reconnect financial reward with lower treatment costs. Meaningful reform requires lawmakers to address the structure of the system, not only the latest fee or contract practice.